Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.

Godman B, Wettermark B, Miranda J, Bennie M, Martin A, Malmström RE.

Int J Clin Pract. 2013 Sep;67(9):853-62. doi: 10.1111/ijcp.12130. Epub 2013 Apr 8.

PMID:
23560825
2.

Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.

Hesse U, Godman B, Petzold M, Martin A, Malmström RE.

Appl Health Econ Health Policy. 2013 Dec;11(6):677-85. doi: 10.1007/s40258-013-0059-4.

PMID:
24105097
3.

Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?

Kalaba M, Godman B, Vuksanović A, Bennie M, Malmström RE.

J Comp Eff Res. 2012 Nov;1(6):539-49. doi: 10.2217/cer.12.62.

PMID:
24236473
4.

Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?

Bennie M, Bishop I, Godman B, Campbell S, Miranda J, Finlayson AE, Gustafsson LL.

Qual Prim Care. 2013;21(1):7-15.

PMID:
23735629
5.

Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future.

Vončina L, Strizrep T, Godman B, Bennie M, Bishop I, Campbell S, Vlahović-Palčevski V, Gustafsson LL.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):469-79. doi: 10.1586/erp.11.42.

PMID:
21831028
6.

Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications.

Martin A, Godman B, Miranda J, Tilstone J, Saleem N, Olsson E, Acosta A, Restrepo L, Bennie M.

J Comp Eff Res. 2014 Jan;3(1):41-51. doi: 10.2217/cer.13.83.

PMID:
24345256
7.

Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries.

Bucsics A, Godman B, Burkhardt T, Schmitzer M, Malmström RE.

Expert Rev Pharmacoecon Outcomes Res. 2012 Dec;12(6):809-19. doi: 10.1586/erp.12.71.

PMID:
23252361
8.

Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.

Bennie M, Bishop I, Godman B, Barbui C, Raschi E, Campbell S, Miranda J, Gustafsson LL.

Int J Clin Pract. 2013 Feb;67(2):170-80. doi: 10.1111/ijcp.12100.

PMID:
23305478
9.

Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.

Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M.

Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):469-82. doi: 10.1586/14737167.2013.820956. Review.

PMID:
23977975
10.

Different initiatives across Europe to enhance losartan utilization post generics: impact and implications.

Moon JC, Godman B, Petzold M, Alvarez-Madrazo S, Bennett K, Bishop I, Bucsics A, Hesse U, Martin A, Simoens S, Zara C, Malmström RE.

Front Pharmacol. 2014 Oct 8;5:219. doi: 10.3389/fphar.2014.00219. eCollection 2014.

11.

Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.

Godman B, Petzold M, Bennett K, Bennie M, Bucsics A, Finlayson AE, Martin A, Persson M, Piessnegger J, Raschi E, Simoens S, Zara C, Barbui C.

BMC Med. 2014 Jun 13;12:98. doi: 10.1186/1741-7015-12-98.

12.

Changes in the utilization of venlafaxine after the introduction of generics in Sweden.

Godman B, Persson M, Miranda J, Skiöld P, Wettermark B, Barbui C, Gustafsson LL.

Appl Health Econ Health Policy. 2013 Aug;11(4):383-93. doi: 10.1007/s40258-013-0037-x.

PMID:
23754677
13.

Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries.

Godman B, Bucsics A, Burkhardt T, Schmitzer M, Wettermark B, Wieninger P.

Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):199-207. doi: 10.1586/erp.10.6.

PMID:
20384566
14.

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.

Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, Bishop I, Bucsics A, Campbell S, Finlayson AE, Fürst J, Garuoliene K, Herholz H, Kalaba M, Laius O, Piessnegger J, Sermet C, Schwabe U, Vlahović-Palčevski VV, Markovic-Pekovic V, Vončina L, Malinowska K, Zara C, Gustafsson LL.

Front Pharmacol. 2014 Jun 17;5:106. doi: 10.3389/fphar.2014.00106. eCollection 2014. Review.

15.
16.

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.

McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A.

Expert Rev Pharmacoecon Outcomes Res. 2010 Feb;10(1):73-85. doi: 10.1586/erp.09.73.

PMID:
20121565
17.

Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.

Zeng W, Gustafsson LL, Bennie M, Finlayson AE, Godman B.

Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):157-69. doi: 10.1586/14737167.2015.963557. Epub 2014 Oct 28.

PMID:
25348709
18.

Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions.

Markovic-Pekovic V, Skrbić R, Godman B, Gustafsson LL.

Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):661-71. doi: 10.1586/erp.12.48.

PMID:
23186404
19.

The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.

Fraeyman J, Van Hal G, Godman B, Beutels P.

Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):141-51. doi: 10.1586/erp.12.88.

PMID:
23402454
20.

[Do generic drugs help control expenditure on hypertension? Apropos of a case].

García AJ, Martos F, Martín A, Sánchez F.

Gac Sanit. 2004 Mar-Apr;18(2):137-44. Spanish.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk